UNASSIGNED: From April 2019 to October 2019, two cases of tricuspid bioprosthetic dysfunction were treated with the J-valve system. Both patients were male, aged 46 and 67 years, respectively. The preoperative evaluation showed that the risk of conventional redo open heart surgery was high. The J-valve implantation was successful in both cases. One patient had slight valve displacement when the transporter was withdrawn during the operation, and a second J-valve was implanted in an ideal position. There was no death, no delayed valve displacement, and no readmission during the follow-up period of 12 months. In both cases, there was an absence of trace tricuspid regurgitation. After 6 months of anticoagulation with warfarin, the patients were converted to long-term aspirin treatment.
UNASSIGNED: The ViV technique with J-valve is feasible and effective in treating tricuspid bioprosthetic SVD in high-risk patients, avoiding cardiopulmonary bypass and conventional thoracotomy injury.
■从2019年4月至2019年10月,用J瓣系统治疗了两例三尖瓣生物假体功能障碍。两个病人都是男性,46岁和67岁,分别。术前评估显示,常规重做心脏直视手术的风险较高。两种情况下的J瓣植入均成功。一名患者在手术过程中取出转运器时瓣膜轻微移位,在理想位置植入了第二个J型瓣膜.没有死亡,无延迟阀门位移,在12个月的随访期内没有再入院。在这两种情况下,没有微量三尖瓣返流。华法林抗凝6个月后,患者转为长期阿司匹林治疗.
■使用J型瓣膜的ViV技术治疗高危患者的三尖瓣生物假体SVD是可行和有效的,避免体外循环和传统开胸手术损伤。